<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02205463</url>
  </required_header>
  <id_info>
    <org_study_id>s14-01171</org_study_id>
    <nct_id>NCT02205463</nct_id>
  </id_info>
  <brief_title>KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer</brief_title>
  <official_title>A Phase Ib Study of KD019 Plus Trastuzumab in Patients With HER2 Overexpressed or Amplified Metastatic or Unresectable Adenocarcinoma of Esophagus, Gastroesophageal Junction and Stomach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This dose-escalation study is to determine the safety, maximum tolerated dose (MTD) and&#xD;
      efficacy of KD019 in combination with trastuzumab and mFOLFOX-6.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, single-arm, dose-escalation phase Ib study to determine the safety,&#xD;
      maximum tolerated dose (MTD) and efficacy of KD019, a multi kinase inhibitor of EGFR, HER2,&#xD;
      Src and VEGFR2, in combination with trastuzumab and mFOLFOX-6 for patients with human&#xD;
      epidermal growth factor receptor 2 positive (HER2+) metastatic or unresectable adenocarcinoma&#xD;
      of esophagus, gastroesophageal junction or stomach.&#xD;
&#xD;
      Patients with HER2+ metastatic or unresectable adenocarcinoma of the esophagus,&#xD;
      gastroesophageal junction or stomach will receive trastuzumab and mFOLFOX-6 in combination&#xD;
      with KD019 to evaluate the safety, toxicity and maximum tolerated dose of this regimen. There&#xD;
      will be four dose cohorts for KD019. KD019 will be administered orally continuously daily on&#xD;
      a 28 day cycle. Trastuzumab and mFOLFOX-6 will be administered as infusions every 2 weeks at&#xD;
      standard doses without escalation. The sequence on the days when all agents are administered&#xD;
      will be KD019 followed by trastuzumab and mFOLFOX-6.&#xD;
&#xD;
      Hypothesis A) KD019, a small molecule inhibitor of multiple receptor tyrosine kinases&#xD;
      including EGFR, HER2, VEGFR-2 and Src, can be safely added, in an effective dose, to the&#xD;
      every 2 week schedule of mFOLFOX-6 + trastuzumab for patients with metastatic or unresectable&#xD;
      HER2+ adenocarcinoma of esophagus, GEJ or stomach&#xD;
&#xD;
      B) When added to mFOLFOX-6 + trastuzumab, KD019will increase response duration, progression&#xD;
      free survival&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      To assess the safety, tolerability, maximum tolerated dose (MTD), recommended phase II dosing&#xD;
      (RP2D) of KD019 in combination of trastuzumab and mFOLFOX-6&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        1. To characterize the pharmacokinetics (PK) parameters of KD019 administered once daily in&#xD;
           combination with every 2 week mFOLFOX-6 and trastuzumab in subjects with metastatic or&#xD;
           unresectable HER2+ adenocarcinoma of the esophagus, gastroesophageal junction (GEJ) and&#xD;
           stomach.&#xD;
&#xD;
        2. To evaluate tumor biopsy specimens pre- and post- treatment with KD019 and trastuzumab&#xD;
           for changes in target receptors and correlate with response&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    IND application withdrawn&#xD;
  </why_stopped>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>28 Days</time_frame>
    <description>To determine maximum tolerated dose (MTD) and RP2D of KD019 in combination with trastuzumab and mFOLFOX-6 when given to patients with HER2+ metastatic or unresectable adenocarcinoma of the esophagus, GEJ or stomach (gastric).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>3 Years</time_frame>
    <description>Progression-free survival (PFS) is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Tumor assessments will be performed using RECIST criteria (Version 1.1). Imaging scans may be done within 4 weeks prior to the first dose of study drug (baseline) and then every 12 weeks (±7 days) after the first dose of study drug until documented progression. Responses will be confirmed by repeat assessments between 28 and 35 days after the response criteria are first met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>3 Years</time_frame>
    <description>Overall response rates are defined as partial response plus complete response. Tumor response will be based on Response evaluation Criteria in Solid Tumors (RECIST 1.1). Response rates will be estimated with exact 95% confidence intervals for each dose level. Kaplan Meier curves will be used to summarize progression free survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>3 Years</time_frame>
    <description>The duration of overall response is measured from the time measurement are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Tumor response will be based on Response evaluation Criteria in Solid Tumors (RECIST 1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate</measure>
    <time_frame>3 Years</time_frame>
    <description>Clinical benefit rate is defined as complete response plus partial response plus stable disease &gt;16 weeks, and will be summarized descriptively. Tumor response will be based on Response evaluation Criteria in Solid Tumors (RECIST 1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of KD019</measure>
    <time_frame>Multiple</time_frame>
    <description>Patients will undergo pharmacokinetics at the following time points:&#xD;
Pre- 15 minutes pre-dosing: C1 D1, C1 D15 and then D1 only starting cycle 2 and thereafter Up to and including the cycle 6 visit.&#xD;
Post- at 1 hour, 2 hours, and 4-6 hours post dosing: C1 D1, C1 D15 and 4-6 hours post dosing only on D1 only starting cycle 2 .&#xD;
A PK sample will also be drawn if QTc(f) interval increases to an absolute value of &gt;500 msec. The concentration of KD019 in these samples will be used to confirm exposure to KD019 and to further characterize the plasma PK of KD019 in this subject population.&#xD;
30 days post treatment visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Stomach Cancer</condition>
  <arm_group>
    <arm_group_label>KD019</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with HER2+ metastatic or unresectable adenocarcinoma of the esophagus, gastroesophageal junction or stomach will receive trastuzumab and mFOLFOX-6 in combination with KD019 to evaluate the safety, toxicity and MTD of this regimen. There will be four dose cohorts for KD019. KD019 will be administered orally continuously daily on a 28 day cycle. Trastuzumab and mFOLFOX-6 will be administered as infusions every 2 weeks at standard doses without escalation. The sequence on the days when all agents are administered will be KD019 followed by trastuzumab and mFOLFOX-6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KD019</intervention_name>
    <arm_group_label>KD019</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must meet all of the following inclusion criteria to be eligible for enrollment&#xD;
        into the study:&#xD;
&#xD;
          -  Pathologically confirmed diagnosis of adenocarcinoma of stomach, GEJ or esophagus&#xD;
             (central confirmation is not required). Primary tumor or metastatic lesion must be&#xD;
             HER2+ documented as HER2 gene amplification by FISH as positive (HER2:CEP17 ratio of&#xD;
             ≥2.0) or IHC 3+.&#xD;
&#xD;
          -  Metastatic or unresectable adenocarcinoma of stomach, GEJ, or esophagus that is&#xD;
             evaluable or that is measurable for response as per RECIST 1.1 criteria, defined as at&#xD;
             least one lesion that can be accurately measured in at least one dimension (longest&#xD;
             diameter to be recorded) as &gt;20 mm with conventional techniques or as &gt;10 mm with&#xD;
             spiral computed tomography (CT) scan.&#xD;
&#xD;
          -  Adult subjects greater than 18 years of age&#xD;
&#xD;
          -  Patients who received postoperative adjuvant therapy with a single-agent&#xD;
             fluoropyrimidine and radiation are eligible.&#xD;
&#xD;
          -  Eastern cooperative oncology group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          -  Adequate organ and bone marrow functions defined as follows:&#xD;
&#xD;
        oAbsolute neutrophil count &gt;1,500 cells/ul&#xD;
&#xD;
          -  Platelets &gt;100,000/ul&#xD;
&#xD;
          -  Hemoglobin &gt;9.0g/dl&#xD;
&#xD;
          -  INR &lt; or equal to 1.5 or INR &lt; or equal to 3 if patient is on warfarin&#xD;
&#xD;
          -  Serum creatinine &lt; or equal to 1.5 times upper limit of normal (ULN) or calculated&#xD;
             creatinine clearance (CRCL) &gt; or equal to 60ml/min&#xD;
&#xD;
          -  Serum electrolytes within the normal range (per institution standard) during&#xD;
             screening.&#xD;
&#xD;
          -  Total bilirubin less than or equal to 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; or equal to 3&#xD;
             times ULN&#xD;
&#xD;
          -  Albumin &gt; or equal to 3g/dL&#xD;
&#xD;
               -  No history of another malignancy in the past 5 years, except treated non-melanoma&#xD;
                  skin cancer or superficial bladder cancer or carcinoma-in-situ of the cervix&#xD;
&#xD;
               -  No coexisting medical problems of sufficient severity to limit compliance with&#xD;
                  the study&#xD;
&#xD;
               -  Ability to understand and sign a written informed consent document. Patient must&#xD;
                  have willingness and ability to comply with scheduled visits, treatment plans,&#xD;
                  laboratory tests and other study procedures.&#xD;
&#xD;
               -  Female subjects of childbearing potential must have a negative serum pregnancy&#xD;
                  test prior to study entry (positive urine tests are to be confirmed by serum&#xD;
                  test).&#xD;
&#xD;
               -  Female subjects of childbearing potential and males must agree to use a highly&#xD;
                  effective method of contraception (&lt;1% per year failure rate) for the duration of&#xD;
                  study treatment and for six months after discontinuation of the study drug.&#xD;
                  Highly effective birth control methods include implants, injectables, combined&#xD;
                  oral contraceptives, some IUDs, sexual abstinence, or vasectomy for males.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment chemotherapy or HER2-directed therapy for metastatic gastric, GEJ or&#xD;
             esophageal adenocarcinoma chemotherapy.&#xD;
&#xD;
          -  Prior peri-operative therapy with a platinum-containing regimen.&#xD;
&#xD;
          -  Angina secondary to fluoropyrimidine therapy in the adjuvant setting&#xD;
&#xD;
          -  Surgery, radiotherapy, or lesion ablative procedure to the only area of&#xD;
             measurable/evaluable disease.&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to the first dose of KD019&#xD;
&#xD;
          -  Left ventricular ejection fraction (EF) &lt;50% at baseline as measured by multi-gated&#xD;
             acquisition (MUGA) scan or echocardiogram (ECHO).&#xD;
&#xD;
          -  Treatment with chronic immunosuppressants (e.g. cyclosporine following&#xD;
             transplantation)&#xD;
&#xD;
          -  Current known active infection with HIV, hepatitis B or C viruses&#xD;
&#xD;
          -  Uncontrolled systemic disease&#xD;
&#xD;
          -  Brain metastases that are:&#xD;
&#xD;
               -  Untreated or&#xD;
&#xD;
               -  Progressive or&#xD;
&#xD;
               -  Have required any type of therapy (including radiation, surgery, steroids or&#xD;
                  anticonvulsant therapy) to control symptoms from brain metastases within 60 days&#xD;
                  prior to the first study treatment&#xD;
&#xD;
               -  Leptomeningeal&#xD;
&#xD;
               -  Hemorrhagic&#xD;
&#xD;
          -  Subject has evidence of pre-existing idiopathic pulmonary fibrosis on CT scan at&#xD;
             baseline&#xD;
&#xD;
          -  History of an invasive secondary primary malignancy diagnosed within the previous 3&#xD;
             years, except for appropriately treated stage I endometrial or cervical carcinoma,&#xD;
             prostate carcinoma treated surgically or non-melanoma skin cancer.&#xD;
&#xD;
          -  No other non-protocol antineoplastic agents will be permitted during this study&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents.&#xD;
&#xD;
          -  Women who are pregnant or lactating.&#xD;
&#xD;
          -  Subject has any of the following EKG criteria:&#xD;
&#xD;
               -  Corrected QT interval (QTc) of &gt;0.47 seconds&#xD;
&#xD;
               -  Finding of a left bundle branch block or right bundle bunch block&#xD;
&#xD;
          -  Bradycardia defined as a heart rate of &lt;50 beats per minute (bpm)&#xD;
&#xD;
          -  Presence of a pacemaker or implantable cardioverter defibrillator (ICD)&#xD;
&#xD;
          -  History of sustained ventricular arrhythmias (subjects with a history of atrial&#xD;
             arrhythmias should be discussed with the sponsor before entry into the study)&#xD;
&#xD;
          -  Family history of congenital long QT syndrome or unexplained sudden death.&#xD;
&#xD;
          -  Moderate or severe pulmonary dysfunction&#xD;
&#xD;
          -  History of clinically significant cardiac dysfunction including:&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  History of myocardial infarction (MI) within 6 months prior to first study&#xD;
                  treatment&#xD;
&#xD;
               -  History of symptomatic CHF (grade &gt;3 by NCI CTCAE or Class &gt;II by New York Heart&#xD;
                  Association (NYHA) criteria or serious cardiac arrhythmia requiring treatment,&#xD;
                  with the exception of atrial fibrillation and paroxysmal supraventricular&#xD;
                  tachycardia&#xD;
&#xD;
               -  Uncontrolled hypertension defined as systolic blood pressure (SBP) ≥ 160 and/or&#xD;
                  diastolic blood pressure (DBP) ≥ 100 despite maximal medical therapy.&#xD;
&#xD;
          -  Subject requires treatment with drugs known to be associated with torsades de pointes&#xD;
             or significant QT interval prolongation.&#xD;
&#xD;
               -  Patients will be eligible for the study if they discontinue any medications&#xD;
                  listed in one week prior to registration and study enrollment.&#xD;
&#xD;
               -  Stable regimen of antidepressants of the SSRI class is allowed (common SSRIs&#xD;
                  include escitalopram oxalate, citalopram, fluvoxamine, paroxetine, sertraline and&#xD;
                  fluoxetine)&#xD;
&#xD;
          -  Use of cytochrome P450 enzyme-inducing anti-epileptic drugs (such as phenytoin,&#xD;
             carbamazepine or phenobarbital) is not allowed.&#xD;
&#xD;
          -  Subject has a serum potassium or magnesium level outside the normal range despite&#xD;
             repletion.&#xD;
&#xD;
          -  Has gastrointestinal tract disease resulting in an inability to take or absorb oral&#xD;
             medication.&#xD;
&#xD;
          -  Inclusion or exclusion of patients on other medications, or severe acute/chronic&#xD;
             medical or psychiatric conditions or laboratory abnormality that may increase the risk&#xD;
             associated with study participation or study drug administration, or may interfere&#xD;
             with the interpretation of study results will be at the judgment of the study&#xD;
             investigator.&#xD;
&#xD;
          -  Subject is unable or unwilling to abide by the study protocol or cooperate fully with&#xD;
             the investigator or designee.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 29, 2014</study_first_submitted>
  <study_first_submitted_qc>July 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2014</study_first_posted>
  <last_update_submitted>July 31, 2014</last_update_submitted>
  <last_update_submitted_qc>July 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esophagus</keyword>
  <keyword>Gastroesophageal Junction</keyword>
  <keyword>Stomach</keyword>
  <keyword>Gastric</keyword>
  <keyword>Cancer</keyword>
  <keyword>HER2</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02205463
org study id: s14-01171
nct id: NCT02205463
lead sponsor: 
has dmc: Yes
This dose-escalation study is to determine the safety, maximum tolerated dose (MTD) and
      efficacy of KD019 in combination with trastuzumab and mFOLFOX-6.
This is an open-label, single-arm, dose-escalation phase Ib study to determine the safety,
      maximum tolerated dose (MTD) and efficacy of KD019, a multi kinase inhibitor of EGFR, HER2,
      Src and VEGFR2, in combination with trastuzumab and mFOLFOX-6 for patients with human
      epidermal growth factor receptor 2 positive (HER2+) metastatic or unresectable adenocarcinoma
      of esophagus, gastroesophageal junction or stomach.

      Patients with HER2+ metastatic or unresectable adenocarcinoma of the esophagus,
      gastroesophageal junction or stomach will receive trastuzumab and mFOLFOX-6 in combination
      with KD019 to evaluate the safety, toxicity and maximum tolerated dose of this regimen. There
      will be four dose cohorts for KD019. KD019 will be administered orally continuously daily on
      a 28 day cycle. Trastuzumab and mFOLFOX-6 will be administered as infusions every 2 weeks at
      standard doses without escalation. The sequence on the days when all agents are administered
      will be KD019 followed by trastuzumab and mFOLFOX-6.

      Hypothesis A) KD019, a small molecule inhibitor of multiple receptor tyrosine kinases
      including EGFR, HER2, VEGFR-2 and Src, can be safely added, in an effective dose, to the
      every 2 week schedule of mFOLFOX-6 + trastuzumab for patients with metastatic or unresectable
      HER2+ adenocarcinoma of esophagus, GEJ or stomach

      B) When added to mFOLFOX-6 + trastuzumab, KD019will increase response duration, progression
      free survival

      Primary objective:

      To assess the safety, tolerability, maximum tolerated dose (MTD), recommended phase II dosing
      (RP2D) of KD019 in combination of trastuzumab and mFOLFOX-6

      Secondary objectives:

        1. To characterize the pharmacokinetics (PK) parameters of KD019 administered once daily in
           combination with every 2 week mFOLFOX-6 and trastuzumab in subjects with metastatic or
           unresectable HER2+ adenocarcinoma of the esophagus, gastroesophageal junction (GEJ) and
           stomach.

        2. To evaluate tumor biopsy specimens pre- and post- treatment with KD019 and trastuzumab
           for changes in target receptors and correlate with response
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Maximum Tolerated Dose (MTD)
time frame: 28 Days
description: To determine maximum tolerated dose (MTD) and RP2D of KD019 in combination with trastuzumab and mFOLFOX-6 when given to patients with HER2+ metastatic or unresectable adenocarcinoma of the esophagus, GEJ or stomach (gastric).
measure: Progression-Free Survival
time frame: 3 Years
description: Progression-free survival (PFS) is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Tumor assessments will be performed using RECIST criteria (Version 1.1). Imaging scans may be done within 4 weeks prior to the first dose of study drug (baseline) and then every 12 weeks (±7 days) after the first dose of study drug until documented progression. Responses will be confirmed by repeat assessments between 28 and 35 days after the response criteria are first met.
measure: Objective Response Rate
time frame: 3 Years
description: Overall response rates are defined as partial response plus complete response. Tumor response will be based on Response evaluation Criteria in Solid Tumors (RECIST 1.1). Response rates will be estimated with exact 95% confidence intervals for each dose level. Kaplan Meier curves will be used to summarize progression free survival.
measure: Duration of Response
time frame: 3 Years
description: The duration of overall response is measured from the time measurement are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Tumor response will be based on Response evaluation Criteria in Solid Tumors (RECIST 1.1).
measure: Clinical Benefit Rate
time frame: 3 Years
description: Clinical benefit rate is defined as complete response plus partial response plus stable disease >16 weeks, and will be summarized descriptively. Tumor response will be based on Response evaluation Criteria in Solid Tumors (RECIST 1.1).
measure: Pharmacokinetics of KD019
time frame: Multiple
description: Patients will undergo pharmacokinetics at the following time points:
Pre- 15 minutes pre-dosing: C1 D1, C1 D15 and then D1 only starting cycle 2 and thereafter Up to and including the cycle 6 visit.
Post- at 1 hour, 2 hours, and 4-6 hours post dosing: C1 D1, C1 D15 and 4-6 hours post dosing only on D1 only starting cycle 2 .
A PK sample will also be drawn if QTc(f) interval increases to an absolute value of >500 msec. The concentration of KD019 in these samples will be used to confirm exposure to KD019 and to further characterize the plasma PK of KD019 in this subject population.
30 days post treatment visit.
arm group label: KD019
arm group type: Experimental
description: Patients with HER2+ metastatic or unresectable adenocarcinoma of the esophagus, gastroesophageal junction or stomach will receive trastuzumab and mFOLFOX-6 in combination with KD019 to evaluate the safety, toxicity and MTD of this regimen. There will be four dose cohorts for KD019. KD019 will be administered orally continuously daily on a 28 day cycle. Trastuzumab and mFOLFOX-6 will be administered as infusions every 2 weeks at standard doses without escalation. The sequence on the days when all agents are administered will be KD019 followed by trastuzumab and mFOLFOX-6.
intervention type: Drug
intervention name: KD019
arm group label: KD019
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Jennifer Wu, MD
role: Principal Investigator
affiliation: NYU Langone Medical Center
facility: 
country: United States
responsible party type: Sponsor
mesh term: Stomach Neoplasms